Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Schuler

Showing results (281-290 of 300) with videos related to

Pageof 30
Sort By:
The Journal of Clinical Investigation|May 20, 2020
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapyLina Such, Fang Zhao, Derek Liu, et al.
Thoracic Cancer|November 20, 2025
Pathologic Complete Response Predicts Long-Term Survival Following Neoadjuvant Induction Chemotherapy and Chemo-Radiotherapy in Stage-III Non-Small Cell Lung CancerMaja Guberina, Martin Metzenmacher, Christoph Pöttgen, et al.
Nature Medicine|May 28, 2025
Molecular determinants of sotorasib clinical efficacy in KRAS<sup>G12C</sup>-mutated non-small-cell lung cancerFerdinandos Skoulidis, Bob T Li, Adrianus Johannes de Langen, et al.
Future Oncology (London, England)|March 25, 2025
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summaryAdrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.
Lancet (London, England)|February 10, 2023
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS<sup>G12C</sup> mutation: a randomised, open-label, phase 3 trialAdrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.
NPJ Digital Medicine|October 14, 2025
Leveraging Sarcopenia index by automated CT body composition analysis for pan cancer prognostic stratificationKatarzyna Borys, Johannes Haubold, Julius Keyl, et al.
European Heart Journal|August 30, 2025
Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial)Markus S Anker, Amir A Mahabadi, Matthias Totzeck, et al.
Nature Cancer|January 30, 2025
Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligenceJulius Keyl, Philipp Keyl, Grégoire Montavon, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumorsStephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.
The Lancet. Oncology|October 26, 2016
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah-Eddin Al-Batran, Ralf D Hofheinz, Claudia Pauligk, et al.
Pageof 30

Showing results (281-290 of 300) with videos related to

Sort By:
Pageof 30
The Journal of Clinical Investigation|May 20, 2020
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapyLina Such, Fang Zhao, Derek Liu, et al.
Thoracic Cancer|November 20, 2025
Pathologic Complete Response Predicts Long-Term Survival Following Neoadjuvant Induction Chemotherapy and Chemo-Radiotherapy in Stage-III Non-Small Cell Lung CancerMaja Guberina, Martin Metzenmacher, Christoph Pöttgen, et al.
Nature Medicine|May 28, 2025
Molecular determinants of sotorasib clinical efficacy in KRAS<sup>G12C</sup>-mutated non-small-cell lung cancerFerdinandos Skoulidis, Bob T Li, Adrianus Johannes de Langen, et al.
Future Oncology (London, England)|March 25, 2025
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summaryAdrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.
Lancet (London, England)|February 10, 2023
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS<sup>G12C</sup> mutation: a randomised, open-label, phase 3 trialAdrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.
NPJ Digital Medicine|October 14, 2025
Leveraging Sarcopenia index by automated CT body composition analysis for pan cancer prognostic stratificationKatarzyna Borys, Johannes Haubold, Julius Keyl, et al.
European Heart Journal|August 30, 2025
Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial)Markus S Anker, Amir A Mahabadi, Matthias Totzeck, et al.
Nature Cancer|January 30, 2025
Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligenceJulius Keyl, Philipp Keyl, Grégoire Montavon, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumorsStephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.
The Lancet. Oncology|October 26, 2016
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah-Eddin Al-Batran, Ralf D Hofheinz, Claudia Pauligk, et al.
Pageof 30